Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)
Back to Freepaper Session

Wavefront-guided LASIK using a fourier-based treatment algorithm with a new wavefront system: the first 100 cases

Session Details

Session Title: LASIK

Session Date/Time: Wednesday 09/10/2013 | 08:00-10:30

Paper Time: 09:20

Venue: Auditorium (First Floor)

First Author: : J.Tellouck FRANCE

Co Author(s): :    D. Smadja   D. Touboul   J. Colin        

Abstract Details

Purpose:

To evaluate the safety and efficacy of myopic wavefront-guided LASIK with the S4 excimer laser (Visx) using a new wavefront sytem with Fourier-based treatment algorithms

Setting:

Ophtalmology Department, University Hospital of Bordeaux

Methods:

This prospective study included 100 eyes of 56 patients treated for myopia with the Advanced CustomVue LASIK using the S4 excimer laser and Fourier treatment tables generated from the iDesign wavefront system (Abbott Medical Optics). Mean spherical equivalent (MRSE), uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and higher wavefront analyses were analyzed at 1month postoperatively.

Results:

Mean patient age was 30,6 +/-9,9 years (range: 22 to 59 years), and mean preoperative manifest refraction spherical equivalent (MRSE) was -4,05 +/- 1,62 D (range: -2,00 to -6,50 D). At 1 month postoperative, MRSE was -0.16 +/- 0.45 D (range: 0 to -1,5 D); 100% of eyes were within 0,5 D of intended correction. Uncorrected visual acuity (UCVA) of 20/20 or better was achieved in 100% of eyes; All eyes had no change or gained at least 1 Snellen line of BSCVA. Higher order aberrations and spherical aberrations root-mean-square increased by 0.053 ?m and 0.09 ?m respectively post-operatively.

Conclusions:

These data support the safety and efficacy of wavefront-guided LASIK using the iDesign wavefront system for the correction of myopia.

Financial Interest:

NONE


loading Please wait while information is loading.